Current limitations and future opportunities for epigenetic therapies

Future Medicinal Chemistry

Volumn 4, Issue 4, 2012, Pages 425-446

  Cherblanc, F ^a   Chapman Rothe, N ^b   Brown, R ^b   Fuchter, M J ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 DEAZANEPLANOCIN A; 5 AZA 2' DEOXYCYTIDINE; ADENOSYL LEVO HOMOCYSTEINE; ANTINEOPLASTIC AGENT; AZACITIDINE; BIX 01294; BIX 01338; BIX 10294; CHETOCIN; DNA METHYLATING AGENT; E 72; ENTINOSTAT; EPZ 004777; HISTONE DEACETYLASE INHIBITOR; ISOLIQUIRITIGENIN; METHYLTHIOADENOSINE; MOCETINOSTAT; N PHTHALOYLTRYPTOPHAN; PANOBINOSTAT; PCI 34051; PSAMMAPLIN A; ROMIDEPSIN; SINEFUNGIN; TUBACIN; UNC 0321; UNC 0631; UNC 0638; UNC 0646; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VORINOSTAT;

DNA METHYLATION; DRUG ACTIVITY; DRUG STRUCTURE; EPIGENETICS; GENE THERAPY; HEMATOLOGIC MALIGNANCY; HISTONE MODIFICATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; SOLID TUMOR;

ANIMALS; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; ENZYME ACTIVATION; ENZYME INHIBITORS; EPIGENOMICS; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HISTONE-LYSINE N-METHYLTRANSFERASE; HISTONES; HUMANS; NEOPLASMS; SMALL MOLECULE LIBRARIES;

EID: 84863384188     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.12.7     Document Type: Review

References (181)

1. Jones PA, Baylin SB. The epigenomics of cancer. Cell 128, 683-692 (2007). (Pubitemid 46273572)
2. Feinberg AP, Ohlsson R, Henikoff S. The epigenetic progenitor origin of human cancer. Nat. Rev. Genet. 7(1), 21-33 (2006). (Pubitemid 41828945)
3. Jurkowska RZ, Jurkowski TP, Jeltsch A. Structure and function of mammalian DNA methyltransferases. ChemBioChem 12(2), 206-222 (2011).
4. Jones PA, Liang GN. Rethinking how DNA methylation patterns are maintained. Nat. Rev. Genet. 10(11), 805-811 (2009).
5. Klose RJ, Bird AP. Genomic DNA methylation: the mark and its mediators. Trends Biochem. Sci. 31(2), 89-97 (2006). (Pubitemid 43221841)
6. Watt F, Molloy Pl. Cytosine methylation prevents binding to DNA of a Hela-cell transcription factor required for optimal expression of the adenovirus major late promoter. Genes Dev. 2(9), 1136-1143 (1988).
7. Boyes J, Bird A. DNA methylation inhibits transcription indirectly via a methyl-Cpg binding-protein. Cell 64(6), 1123-1134 (1991). (Pubitemid 121001199)
8. Wade PA. Methyl CpG binding proteins: coupling chromatin architecture to gene regulation. Oncogene 20(24), 3166-3173 (2001). (Pubitemid 32553572)
9. Strahl BD, Allis CD. The language of covalent histone modifications. Nature 403(6765), 41-45 (2000). (Pubitemid 30038513)
10. Lall S. Primers on chromatin. Nat. Struct. Biol. 14(11), 1110-1115 (2007). (Pubitemid 350060326)
11. Bannister AJ, Kouzarides T. Regulation of chromatin by histone modifications. Cell Res. 21(3), 381-395 (2011).
12. Suganuma T, Workman JL. Signals and combinatorial functions of histone modifications. Annu. Rev. Biochem. 80, 473-499 (2011).
13. Kouzarides T. Chromatin modifications and their function. Cell 128(4), 693-705 (2007). (Pubitemid 46273577)
14. Wiencke JK, Zheng S, Morrison Z, Yeh RF. Differentially expressed genes are marked by histone 3 lysine 9 trimethylation in human cancer cells. Oncogene 27(17), 2412-2421 (2008). (Pubitemid 351521100)
15. Feinberg AP, Gehrke CW, Kuo KC, Ehrlich M. Reduced genomic 5-methylcytosine content in human colonic neoplasia. Cancer Res. 48(5), 1159-1161 (1988). (Pubitemid 18075525)
16. Lapeyre J-N, Becker FF. 5-methylcytosine content of nuclear DNA during chemical hepatocarcinogenesis and in carcinomas which result. Biochem. Biophys. Res. Commun. 87(3), 698-705 (1979). (Pubitemid 9178100)
17. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med. 349(21), 2042-2054 (2003). (Pubitemid 37448928)
18. Chen RZ, Pettersson U, Beard C, Jackson-Grusby L, Jaenisch R. DNA hypomethylation leads to elevated mutation rates. Nature 395(6697), 89-93 (1998). (Pubitemid 28420236)
19. Taby R, Issa J-PJ. Cancer epigenetics. CA Cancer J. Clin. 60(6), 376-392 (2010).
20. Eden A, Gaudet F, Waghmare A, Jaenisch R. Chromosomal instability and tumors promoted by DNA hypomethylation. Science 300(5618), 455 (2003). (Pubitemid 36444319)
21. Toyota M, Issa J-PJ. The role of DNA hypermethylation in human neoplasia. Electrophoresis 21(2), 329-333 (2000). (Pubitemid 30074723)
22. Esteller M. CpG island hypermethylation and tumor suppressor genes: a booming present, brighter future. Oncogene 21(35) 5427-5440 (2002). (Pubitemid 34983479)
23. Esteller M. Epigenetic gene silencing in cancer: the DNA hypermethylome. Hum. Mol. Gen. 16(R1), R50-R59 (2007). (Pubitemid 47241842)
24. Tsai HC, Baylin SB. Cancer epigenetics: linking basic biology to clinical medicine. Cell Res. 21(3), 502-517 (2011).
25. Schuebel KE, Chen W, Cope L et al. Comparing the DNA hypermethylome with gene mutations in human colorectal cancer. PLos Genet. 3(9), 1709-1723 (2007). (Pubitemid 47510263)
26. Zardo G, Tirikainen MI, Hong CB et al. Integrated genomic and epigenomic analyses pinpoint biallelic gene inactivation in tumors. Nat. Genet. 32(3), 453-458 (2002). (Pubitemid 35266125)
27. Zhu P, Martin E, Mengwasser J, Schlag P, Janssen KP, Gottlicher M. Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell 5(5), 455-463 (2004). (Pubitemid 38610247)
28. Ropero S, Fraga MF, Ballestar E et al. A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition. Nat. Genet. 38(5), 566-569 (2006).
29. Moore SDP, Herrick SR, Ince TA et al. Uterine leiomyomata with t(10;17) disruptthe histone acetyltransferase MORF. Cancer Res. 64(16), 5570-5577 (2004). (Pubitemid 39095551)
30. Bryan EJ, Jokubaitis VJ, Chamberlain NL et al. Mutation analysis of EP300 in colon, breast and ovarian carcinomas. Int. J. Cancer 102(2), 137-141 (2002). (Pubitemid 35168025)
31. Dalgliesh GL, Furge K, Greenman C et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 463(7279), 360-363 (2010).
32. Hamamoto R, Furukawa Y, Morita M et al. SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. Nat. Cell Biol. 6(8), 731-740 (2004). (Pubitemid 39144478)
33. Portela A, Esteller M. Epigenetic modifications and human disease. Nat. Biotechnol. 28, 1057-1068 (2010).
34. Fraga MF, Ballestar E, Villar-Garea A et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat. Genet. 37(4), 391-400 (2005).
35. Kondo Y, Shen L, Suzuki S et al. Alterations of DNA methylation and histone modifications contribute to gene silencing in hepatocellular carcinomas. Hepatol. Res. 37(11), 974-983 (2007). (Pubitemid 47399927)
36. Vire E, Brenner C, Deplus R et al. The Polycomb group protein EZH2 directly controls DNA methylation. Nature 439(7078), 871-874 (2006). (Pubitemid 43255707)
37. Derks S, Bosch LJW, Niessen HEC et al. Promoter CpG island hypermethylation- and H3K9me3 and H3K27me3-mediated epigenetic silencing targets the deleted in colon cancer (DCC) gene in colorectal carcinogenesis without affecting neighboring genes on chromosomal region 18q21. Carcinogenesis 30(6), 1041-1048 (2009).
38. Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat. Genet. 21(1), 103-107 (1999). (Pubitemid 29036293)
39. Plumb JA, Steele N, Finn P, Brown R. Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo. Br. J. Cancer 100(5), 758-763 (2009).
40. Issa JP, Kantarjian HM. Targeting DNA methylation. Clin. Cancer Res. 15, 3938-3946 (2009).
41. Weinstein IB, Joe A. Oncogene addiction. Cancer Res. 68(9), 3077-3080 (2008).
42. Kelly TK, De Carvalho DD, Jones PA. Epigenetic modifications as therapeutic targets. Nat. Biotech. 28(10), 1069-1078 (2010).
43. Plagemann PGW, Behrens M, Abraham D. Metabolism and cytotoxicity of 5-azacytidine in cultured Novikoff rat hepatoma and P388 mouse leukemia-cells and their enhancement by pre-incubation with pyrazofurin. Cancer Res. 38(8), 2458-2466 (1978). (Pubitemid 8390822)
44. Stresemann C, Lyko F: Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int. J. Cancer 123(1), 8-13 (2008). (Pubitemid 351705186)
45. Stresemann C, Brueckner B, Musch T, Stopper H, Lyko F. Functional diversity of DNA methyltransferase inhibitors in human cancer cell lines. Cancer Res. 66(5), 2794-2800 (2006).
46. Chuang JC, Yoo CB, Kwan JM et al. Comparison of biological effects of non-nucleoside DNA methylation inhibitors versus 5-aza-2′-deoxycytidine. Mol. Cancer Ther. 4(10), 1515-1520 (2005). (Pubitemid 41556433)
47. Siedlecki P, Boy RG, Musch T et al. Discovery of two novel, small-molecule inhibitors of DNA methylation. J. Med. Chem. 49(2), 678-683 (2005).
48. Suzuki T, Tanaka R, Hamada S, Nakagawa H, Miyata N. Design, synthesis, inhibitory activity, and binding mode study of novel DNA methyltransferase 1 inhibitors. Bioorg. Med. Chem. Lett. 20(3), 1124-1127 (2010).
49. Piña IC, Gautschi JT, Wang G-Y-S et al. Psammaplins from the sponge Pseudoceratina purpurea: inhibition of both histone deacetylase and DNA methyltransferase. J. Org. Chem. 68(10), 3866-3873 (2003). (Pubitemid 36576636)
50. Nebbioso A, Pereira R, Khanwalkar H et al. Death receptor pathway activation and increase of ROS production by the triple epigenetic inhibitor, UVI5008. Mol. Cancer Ther. 10(12), 2394-2404 (2011).
51. Lin J, Haffner MC, Zhang Y et al. Disulfiram is a DNA demethylating agent and inhibits prostate cancer cell growth. Prostate 71(4), 333-343 (2011).
52. García J, Franci G, Pereira R et al. Epigenetic p rofiling of the antitumor natural product psammaplin A and its analogues. Bioorg. Med. Chem. 19(12), 3637-3649 (2011).
53. Baud MGJ, Leiser T, Haus P et al. Defining the mechanism of action and enzymatic selectivity of psammaplin A against its epigenetic targets. J. Med. Chem. doi: 10.1021/jm2016182 (2012) (Epub ahead of print).
54. Godert AM, Angelino N, Woloszynska-Read A et al. An improved synthesis of psammaplin A. Bioorg. Med. Chem. Lett. 16(12), 3330-3333 (2006)
55. Beisler JA. Isolation, characterization, and properties of a labile hydrolysis product of he antitumor nucleoside, 5-azacytidine. J. Med. Chem. 21(2), 204-208 (1978). (Pubitemid 8269368)
56. Yoo B, Jeong S, Egger G et al. Delivery of 5-aza-5′-deoxycytidine to cells using oligodeoxynucleotides. Cancer Res. 67(13), 6400-6408 (2007). (Pubitemid 47037524)
57. Chabot GG, Rivard E, Momparler RL. Plasma and cerebrospinal-fluid pharmacokinetics of 5-aza-5′- eoxycytidine in rabbits and Dogs. Cancer Res. 43(2), 592-597 (1983). (Pubitemid 13193853)
58. Mcgarvey M, ahrner JA, Greene E, Martens J, Jenuwein T, Baylin SB. Silenced tumor suppressor enes reactivated by DNA demethylation do not return to a fully euchromatic chromatin tate. Cancer Res. 66(7), 3541-3549 (2006).
59. Cheng JC. Preferential response of cancer cells to zebularine. Cancer Cell 6, 151-158 (2004). (Pubitemid 39485687)
60. Chuang JC, Warner SL, Vollmer D et al. S110, a 5-aza-5′- deoxycytidine-containing dinucleotide, is an effective DNA methylation inhibitor in vivo and can reduce tumor growth. Mol. Cancer Ther. 9(5), 1443-1450 (2010).
61. Flotho C, Claus R, Batz C et al. The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia 23(6), 1019-1028 (2009).
62. Zhu WG, Dai ZY, Ding HM et al. Increased expression of unmethylated CDKN2D by 5-aza-5′-deoxycytidine in human lung cancer cells. Oncogene 20(53), 7787-7796 (2001).
63. De Smet C, De Backer O, Faraoni I, Lurquin C, Brasseur F, Boon T. The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. Proc. Natl Acad. Sci. USA 93(14), 7149-7153 (1996). (Pubitemid 26243517)
64. Oki Y, Jelinek J, Shen L, Kantarjian HM, Issa J-PJ. Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemia. Blood 111(4), 2382-2384 (2008). (Pubitemid 351451448)
65. Witt O, Deubzer HE, Milde T, Oehme I. HDAC family: what are the cancer relevant targets? Cancer Lett. 277(1), 8-21 (2009).
66. North B, Verdin E. Sirtuins: Sir2-related NAD-dependent protein deacetylases. Genome Biol. 5(5), 224 (2004).
67. Glozak Ma, Sengupta N, Zhang X, Seto E. Acetylation and deacetylation of non-histone proteins. Gene 363, 15-23 (2005). (Pubitemid 41691888)
68. Yao Y-L, Yang W-M. Beyond histone and deacetylase: an overview of cytoplasmic histone deacetylases and their nonhistone substrates. J. Biomed. Biotechnol. doi:10.1155/2011/146493 (2011) (Epub ahead of print).
69. Wilson BJ, Tremblay AM, Deblois G, Sylvain-Drolet G, Giguère V. An acetylation switch modulates the transcriptional activity of estrogen-related receptor a. Mol. Endocrinol. 24(7), 1349-1358 (2010).
70. Mann M, Choudhary C, Kumar C et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325(5942), 834-840 (2009).
71. Xiong Y, Zhao SM, Xu W et al. Regulation of cellular metabolism by protein lysine acetylation. Science 327(5968), 1000-1004 (2010).
72. Zhao SM, Wang QJ, Zhang YK et al. Acetylation of metabolic enzymes coordinates carbon source utilization and metabolic flux. Science 327(5968), 1004-1007 (2010).
73. Norvell A, Mcmahon SB. Rise of the rival. Science 327(5968), 964-965 (2010).
74. Marks PA, Xu WS, Parmigiani Rb. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 26(37), 5541-5552 (2007). (Pubitemid 47255934)
75. Ellis DJP, Lawman ZK, Bonham K. Histone acetylation is not an accurate predictor of gene expression following treatment with histone deacetylase inhibitors. Biochem. Biophys. Res. Commun. 367(3), 656-662 (2008).
76. Mottet D, Pirotte S, Lamour V et al. HDAC4 represses p21WAF1/Cip1 expression in human cancer cells through a Sp1-dependent, p53-independent mechanism. Oncogene 28(2), 243-256 (2008).
77. Sawa H, Murakami H, Kumagai M et al. Histone deacetylase inhibitor, FK228, induces apoptosis and suppresses cell proliferation of human glioblastoma cells in vitro and in vivo. Acta Neuropathol. 107(6), 523-531 (2004). (Pubitemid 38765394)
78. Richon VM, Sandhoff TW, Rifkind RA, Marks PA. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc. Natl Acad. Sci. USA 97(18), 10014-10019 (2000).
79. Schrump DS. Cytotoxicity mediated by histone deacetylase inhibitors in cancer cells: mechanisms and potential clinical implications. Clin. Cancer Res. 15(12), 3947-3957 (2009).
80. Chen Cs, Weng SC, Tseng PH, Lin HP. Histone acetylation-independent effect of histone deacetylase inhibitors on Akt through the reshuffling of protein phosphatase 1 complexes. J. Biol. Chem. 280(46), 38879-38887 (2005).
81. Rhodes LV, Nitschke AM, Segar HC et al. The histone deacetylase inhibitor trichostatin A alters microRNA expression profiles in apoptosis-resistant breast cancer cells. Oncol. Rep. (1), 10-16 (2011).
82. Brest P, Lassalle S, Hofman V et al. MiR-129 5p is required for histone deacetylase inhibitor-induced cell death in thyroid cancer cells. Endocr Relat Cancer 18(6), 711-719 (2011).
83. Lane AA, Chabner BA. Histone deacetylase inhibitors in cancer therapy. J. Clin. Oncol. 27, 5459-5468 (2009).
84. Baud MGJ, Leiser T, Meyer-Almes F-J, Fuchter MJ. New synthetic strategies towards psammaplin A, access to natural product analogues for biological evaluation. Org. Biomol. Chem. 9(3), 659-662 (2011).
85. Peter A. Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges. Cancer Lett. 280(2), 233-241 (2009).
86. Mann BS, Johnson JR Cohen MH, Justice R, Pazdur R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 12(10), 1247-1252 (2007). (Pubitemid 350106355)
87. Marks PA, Breslow R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat. Biotechnol. 25(1), 84-90 (2007). (Pubitemid 46087907)
88. Whittaker SJ, Demierre M-F, Kim EJ et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J. Clin. Oncol. 28(29), 4485-4491 (2010).
89. Piekarz Rl, Frye R, Turner M et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J. Clin. Oncol. 27(32), 5410-5417 (2009).
90. Ma X, Ezzeldin HH, Diasio RB. Histone deacetylase inhibitors: current status and overview of recent clinical trials. Drugs 69, 1911-1934 (2009).
91. Balasubramanian S, Verner E, Buggy JJ. Isoform-specific histone deacetylase inhibitors: the next step? Cancer Lett. 280(2), 211-221 (2009).
92. Graham JS, Kaye SB, Brown R. The promises and pitfalls of epigenetic therapies in solid tumours. Eur. J. Cancer 45(7), 1129-1136 (2009).
93. Siegel D, Hussein M, Belani C et al. Vorinostat in solid and hematologic malignancies. J. Hematol. Oncol. 27(2), 31 (2009).
94. Galanis E, Jaeckle KA, Maurer MJ et al. Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. J. Clin. Oncol. 27(12), 2052-2058 (2009).
95. Steele NL, Plumb JA, Vidal L et al. A Phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin. Cancer Res. 14(3), 804-810 (2008). (Pubitemid 351231163)
96. Modesitt SC, Sill M, Hoffman JS, Bender DP. A Phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecologic Oncol. 109(2) 182-186 (2008).
97. Hussain M, Bradley D, Rathkopf D et al. Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862) trial results and interleukin-6 analysis: a study by the department of defense prostate cancer clinical trial consortium and University of Chicago Phase II consortium. Cancer 115(23), 5541-5549 (2009).
98. Blumenschein GR, Kies MS, Papadimitrakopoulou VA et al. Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer. Invest. New Drugs 26(1), 81-87 (2008).
99. Somlo G, Luu TH, Morgan RJ et al. A Phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium Study. Clin. Cancer Res. 14(21), 7138-7142 (2008).
100. Thaler F, Minucci S. Next generation histone deacetylase inhibitors: the answer to the search for optimized epigenetic therapies? Expert Opin. Drug Disc. 6(4), 393-404 (2011).
101. Toyota M, Shen L, Ohe-Toyota M, Hamilton SR, Sinicrope FA, Issa J-PJ. Aberrant methylation of the cyclooxygenase 2 CpG island in colorectal tumors. Cancer Res. 60(15), 4044-4048 (2000). (Pubitemid 30636581)
102. Chapman-Rothe N, Brown R. Approaches to target the genome and its epigenome in cancer. Future Med. Chem. 1(8), 1481-1495 (2009).
103. Yao X, Hu J-F, Daniels M et al. A methylated oligonucleotide inhibits IGF2 expression and enhances survival in a model of hepatocellular carcinoma. J. Clin. Invest. 111(2), 265-273 (2003). (Pubitemid 36105926)
104. Sasaki H, Moriyama S, Nakashima Y et al. Histone deacetylase 1 mRNA expression in lung cancer. Lung Cancer 46(2), 171-178 (2004). (Pubitemid 39330411)
105. Gao D-J, Xu M, Zhang Y-Q et al. Upregulated histone deacetylase 1 expression in pancreatic ductal adenocarcinoma and specific SiRNA inhibits the growth of cancer cells. Pancreas 39(7) 949-1001 (2010).
106. Zhang Z, Yamashita H, Toyama T et al. Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast. Breast Cancer Res. Tr. 94(1), 11-16 (2005). (Pubitemid 41416937)
107. Krusche C, Wülfing P, Kersting C et al. Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis. Breast Cancer Res. Treat. 90(1), 15-23 (2005). (Pubitemid 40486997)
108. Piekarz RL, Bates SE. Epigenetic modifiers: basic understanding and clinical development. Clin. Cancer Res. 15(12), 3918-3926 (2009).
109. Qin T, Jelinek J, Si J, Shu J, Issa J-PJ. Mechanisms of resistance to 5-aza-5′- deoxycytidine in human cancer cell lines. Blood 113(3), 659-667 (2009).
110. La Thangue NB, Khan O, Fotheringham S et al. HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy. Proc. Natl Acad. Sci. USA 107(14), 6532-6537 (2010).
111. Spannhoff A, Sippl W, Jung M. Cancer treatment of the future: inhibitors of histone methyltransferases. Int. J. Biochem. Cell Biol. 41(1), 4-11 (2009).
112. Spannhoff A, Hauser AT, Heinke R, Sippl W, Jung M. The emerging therapeutic potential of histone methyltransferase and demethylase inhibitors. ChemMedChem 4(10), 1568-1582 (2009).
113. Lohse B, Kristensen JL, Kristensen LH et al. Inhibitors of histone demethylases. Bioorg. Med. Chem. 19(12), 3625-3636 (2011).
114. Allis CD, Berger SL, Cote J et al. New nomenclature for chromatin-modifying enzymes. Cell 131(4), 633-636 (2007). (Pubitemid 350089969)
115. Copeland RA, Solomon ME, Richon VM. Protein methyltransferases as a target class for drug discovery. Nat. Rev. Drug Discov. 8(9), 724-732 (2009).
116. Hansen KH, Bracken AP, Pasini D et al. A model for transmission of the H3K27me3 epigenetic mark. Nat. Cell Biol. 10(11), 1291-1300 (2008).
117. Qian C, Zhou M. SET domain protein lysine methyltransferases: structure, specificity and catalysis. Cell. Mol. Life Sci. 63(23), 2755-2763 (2006). (Pubitemid 44913316)
118. Chuikov S, Kurash JK, Wilson JR et al. Regulation of p53 activity through lysine methylation. Nature 432(7015), 353-360 (2004). (Pubitemid 39551664)
119. Huang J. G9a and Glp methylate lysine 373 in the tumor suppressor p53. J. Biol. Chem. 285, 9636-9641 (2010).
120. Huang J, Perez-Burgos L, Placek Bj et al. Repression of p53 activity by Smyd2-mediated methylation. Nature 444(7119), 629-632 (2006). (Pubitemid 44864441)
121. Shi X, Kachirskaia I, Yamaguchi H et al. Modulation of p53 function by SET8-mediated methylation at lysine 382. Mol. Cell 27(4), 636-646 (2007). (Pubitemid 47238634)
122. Pradhan S, Chin HG, Estève P-O, Jacobsen SE: SET7/9 mediated methylation of non-histone proteins in mammalian cells. Epigenetics 4(6), 383-387 (2009).
123. Yang X-D, Lamb A, Chen L-F. Methylation, a new epigenetic mark for protein stability. Epigenetics 4(7), 429-433 (2009).
124. Rathert P, Dhayalan A, MAH, Jeltsch A. Specificity of protein lysine methyltransferases and methods for detection of lysine methylation of non-histone proteins. Mol. Biosyst. 4(12), 1186-1190 (2008).
125. Bernstein BE, Mikkelsen TS, Xie X et al. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 125(2), 315-326 (2006).
126. Sauvageau M, Sauvageau G. Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer. Cell Stem Cell 7(3), 299-313 (2010).
127. Schwartz YB, Pirrotta V. Polycomb silencing mechanisms and the management of genomic programmes. Nat. Rev. Genet. 8(1), 9-22 (2007). (Pubitemid 46006046)
128. Baylin SB. Stem cells, cancer, and epigenetics. In: Stembook. The Stem Cell Research Community, Baltimore, MD, USA (2009).
129. Simon JA, Lange CA. Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat. Res. Fundam. Mol. Mech. Mutagen. 647(1-2), 21-29 (2008).
130. Clevers H. The cancer stem cell: premises, promises and challenges. Nat. Med. 313-319 (2011).
131. Suvà M-L, Riggi N, Janiszewska M et al. EZH2 is essential for glioblastoma cancer stem cell maintenance. Cancer Res. 69(24), 9211-9218 (2009).
132. Rizzo S, Hersey JM, Mellor P et al. Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2. Mol. Cancer Ther. 10(2), 325-335 (2011).
133. Albert M, Helin K. Histone methyltransferases in cancer. Sem. Cell Dev. Biol. 21(2), 209-220 (2010).
134. Varier RA, Timmers HTM. Histone lysine methylation and demethylation pathways in cancer. BBA-Rev. Cancer 1815(1), 75-89 (2011).
135. Chase A, Cross NC. Aberrations of EZH2 in cancer. Clin. Cancer Res. 17(9), 2613-2618 (2011).
136. Tsang DPF, Cheng ASL. Epigenetic regulation of signaling pathways in cancer: Role of the histone methyltransferase EZH2. J. Gastroen. Hepatol. 26(1), 19-27 (2011).
137. Morin RD, Johnson NA, Severson TM et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat. Genet. 42(2), 181-U124 (2010).
138. Sneeringer CJ, Scott MP, Kuntz KW et al. Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proc. Natl Acad. Sci. 107(49), 20980-20985 (2010).
139. Yap DB, Chu J, Berg T et al. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood 117(8), 2451-2459 (2011).
140. Van Haaften G, Dalgliesh GL, Davies H et al. Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat. Genet. 41(5), 521-523 (2009).
141. Takawa M, Masuda K, Kunizaki M et al. Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker. Cancer Sci. 102(7), 1298-1305 (2011).
142. Smith BC, Denu JM. Chemical mechanisms of histone lysine and arginine modifications. BBA Gene Reg. Mech. 1789(1), 45-57 (2009).
143. Cheng X, Zhang X. Structural dynamics of protein lysine methylation and demethylation. Mutat. Res. Fundam. Mol. Mech. Mutagen. 618(1-2), 102-115 (2007). (Pubitemid 46574740)
144. Chin HG, Patnaik D, Esteve Po, Jacobsen SE, Pradhan S. Catalytic properties and kinetic mechanism of human recombinant lys-9 histone H3 methyltransferase SUV39H1: participation of the chromodomain in enzymatic catalysis. Biochemistry 45(10), 3272-3284 (2006). (Pubitemid 43376346)
145. Patnaik D, Chin HG, Estève P-O, Benner J, Jacobsen Se, Pradhan S. Substrate specificityand kinetic mechanism of mammalian G9a histone H3 methyltransferase. J. Biol. Chem. 279(51), 53248-53258 (2004). (Pubitemid 40051828)
146. Zhang X, Yang Z, Khan Si et al. Structural basis for the product specificity of histone lysine methyltransferases. Mol. Cell 12(1), 177-185 (2003). (Pubitemid 36957834)
147. Zhang X, Bruice TC. Enzymatic mechanism and product specificity of SET-domain protein lysine methyltransferases. Proc. Natl Acad. Sci. USA 105(15), 5728-5732 (2008). (Pubitemid 351758440)
148. Karaman MW, Herrgard S, Treiber DK et al. A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 26(1), 127-132 (2008).
149. Cheng XD, Collins RE, Zhang X. Structural and sequence motifs of protein (histone) methylation enzymes. Annu. Rev. Biophys. Biomol. Struct. 34, 267-294 (2005). (Pubitemid 40847726)
150. Mccammon MT, Parks LW. Inhibition of sterol transmethylation by S-adenosylhomocysteine analogs. J. Bacteriol. 145(1), 106-112 (1981). (Pubitemid 11131848)
151. Daigle SR, Olhava Ej, Therkelsen CA et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell 20(1), 53-65 (2011).
152. Tan J, Yang XJ, Zhuang L et al. Pharmacologic disruption of polycombrepressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev. 21(9), 1050-1063 (2007). (Pubitemid 46686474)
153. Glazer RI, Hartman KD, Knode MC et al. 3-deazaneplanocin: a new and potent inhibitor of S-adenosylhomocysteine hydrolase and its effects on human promyelocytic leukemia-cell line Hl-60. Biochem. Biophys. Res. Commun. 135(2), 688-694 (1986). (Pubitemid 16049461)
154. Chiang PK, Cantoni GL. Perturbation of biochemical transmethylations by 3-deazaadenosine in vivo. Biochem. Pharmacol. 28(12), 1897-1902 (1979). (Pubitemid 9201841)
155. Chiang PK. Biological effects of inhibitors of S-adenosylhomocysteine hydrolase. Pharmacol. Ther. 77(2), 115-134 (1998). (Pubitemid 28077910)
156. Miranda TB, Cortez CC, Yoo CB et al. DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Mol. Cancer Ther. 8, 1579-1588 (2009).
157. Zee BM, Levin RS, Xu B, Leroy G, Wingreen NS, Garcia BA. In vivo residue-specific histone methylation dynamics. J. Biol. Chem. 285(5), 3341-3350 (2010).
158. Fiskus W, Pranpat M, Balasis M et al. Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells. Mol. Cancer Ther. 5(12), 3096-3104 (2006). (Pubitemid 46092051)
159. Fiskus W, Buckley K, Rao R et al. Panobinostat treatment depletes EZH2 and DNMT1 levels and enhances decitabine mediated de-repression of JunB and loss of survival of human acute leukemia cells. Cancer Biol. Ther. 8(10), 939-950 (2009).
160. Fiskus W, Wang YC, Jillella A et al. Combined epigenetic therapy with the novel histone methyl transferase EZH2 inhibitor 3-deazaneplanocin and -histone deacetylase inhibitor panobinostat exerts synergistic activity against human mantle cell lymphoma cells. Blood 112(11), 1239-1239 (2008).
161. Jiang X, Tan J, Li J et al. DACT3 Is an Epigenetic regulator of Wnt/≤-catenin signaling in colorectal cancer and is therapeutic target of histone modifications. Cancer Cell 13(6) 529-541 (2008). (Pubitemid 351766796)
162. Greiner D, Bonaldi T, Eskeland R, Roemer E, Imhof A. Identification of a specific inhibitor of the histone methyltransferase SU(VAR)3-9. Nat. Chem. Biol. 1(3), 143-145 (2005).
163. Hauser D, Weber HP, Sigg HP. Isolation and configuration of Chaetocin. Helv. Chim. Acta 53(5), 1061-1073 (1970).
164. Gardiner DM, Waring P, Howlett BJ. The epipolythiodioxopiperazine (ETP) class of fungal toxins: distribution, mode of action, functions and biosynthesis. Microbiology 151, 1021-1032 (2005). (Pubitemid 40568000)
165. Isham CR, Tibodeau JD, Jin W, Xu RF, Timm MM, Bible KC. Chaetocin: p romising new antimyeloma agent with in vitro and in vivo activity mediated via imposition of oxidative stress. Blood 109(6), 2579-2588 (2007). (Pubitemid 46425905)
166. Cook KM, Hilton ST, Mecinovic J, Motherwell WB, Figg WD, Schofield CJ. epidithiodiketopiperazines block the interaction between hypoxia-inducible factor- 1a (hif-1a) and p300 by a zinc ejection mechanism. J. Biol. Chem. 284(39), 26831-26838 (2009).
167. Saito T, Suzuki Y, Koyama K, Natori S, Iitaka Y, Kinoshita T. chetracin-A and chaetocin-B and chaetocin-C, 3 new epipolythiodioxopiperazines from Chaetomium Spp. Chem. Pharm. Bull. 36(6), 1942-1956 (1988).
168. Iwasa E, Hamashima Y, Fujishiro S et al. Total synthesis of (+)-chaetocin and its analogues: their histone methyltransferase G9a inhibitory activity. J. Am. Chem. Soc. 132, 4078-4079 (2010).
169. Cherblanc F, Lo Y-P, De Gussem E et al. On the determination of the stereochemistry of semisynthetic natural product analogues using chiroptical spectroscopy: desulfurization of epidithiodioxopiperazine fungal metabolites. Chem. Eur. J. 17(42), 11868-11875 (2011).
170. Kubicek S, O'SulliVan RJ, August EM et al. Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase. Mol. Cell 25, 473-481 (2007). (Pubitemid 46206139)
171. Chang Y, Zhang X, Horton Jr et al. Structural basis for G9a-like protein lysine methyltransferase inhibition by BIX-01294. Nat. Struct. Mol. Biol. 16(3), 312-317 (2009).
172. Liu F, Chen X, Allali-Hassani A et al. Discovery of a 2,4-diamino-7- aminoalkoxyquinazoline as a potent and selective inhibitor of histone lysine methyltransferase G9a. J. Med. Chem. 52(24), 7950-7953 (2009).
173. Liu F, Chen X, Allali-Hassani A et al. Protein lysine methyltransferase G9a inhibitors: design, synthesis, and structure activity relationships of 2,4-diamino-7-aminoalkoxyquinazolines. J. Med. Chem. 53(15), 5844-5857 (2010).
174. Liu F, Barsyte-Lovejoy D, Allali-Hassan.i.et al. Optimization of cellular activity of G9a inhibitors 7-aminoalkoxy-quinazolines. J. Med. Chem. 54(17), 6139-6150 (2011).
175. Vedadi M, Barsyte-Lovejoy D, Liu F et al. A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells. Nat. Chem. Biol. 7(8), 566-574 (2011).
176. Chang YQ, Ganesh T, Horton JR et al. Adding a lysine mimic in the design of potent inhibitors of histone lysine methyltransferases. J. Mol. Biol. 400(1), 1-7 (2010).
177. Osborne T, Weller Roska RL, Rajski SR, Thompson PR. In situ generation of bisubstrate analogue for protein arginine methyltransferase 1. J. Am. Chem. Soc. 130(14) 4574-4575 (2008). (Pubitemid 351500080)
178. Dowden J, Hong W, Parry RV, Pike RA, Ward SG. Toward the development of potent and selective bisubstrate inhibitors of protein arginine methyltransferases. Bioorg. Med. Chem. Lett. 20(7), 2103-2105 (2010).
179. Mori S, Iwase K, Iwanami N, Tanaka Y, Kagechika H, Hirano T. Development of novel bisubstrate-type inhibitors of histone methyltransferase SET7/9. Bioorg. Med. Chem. 18(23), 8158-8166 (2010).
180. Howitz KT, Bitterman KJ, Cohen HY et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425(6954), 191-196 (2003). (Pubitemid 37150899)
181. Choi SH, Kim YW, Kim SG. AMPKmediated GSK3[b] inhibition by isoliquiritigenin contributes to protecting mitochondria against iron-catalyzed oxidative stress. Biochem. Pharmacol. 79(9), 1352-1362 (2010).